Top Markets
#1 Zora Zora +42.47%
#2 AI XOVIA AI XOVIA +38.52%
#3 Full Moon Full Moon +19.13%
#4 0G 0G +18.66%
#5 Notcoin Notcoin +15.26%
#6 Axelar Axelar +14.32%
#7 Wrapped NXM Wrapped NXM +12.92%
#8 rsERG rsERG +11.77%
#9 ZKsync ZKsync +10.74%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Kexing Biopharm Co., Ltd. Kexing Biopharm Co., Ltd.

Kexing Biopharm Co., Ltd.

688136
Classement en actions #12397
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily... Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
Prix de l'action
$2.97
Capitalisation boursière
$590.25M
Changement (1 jour)
-5.00%
Changement (1 an)
-52.18%
Pays
CN
Échange Kexing Biopharm Co., Ltd. (688136)

Catégorie

Healthcare
Bénéfices pour Kexing Biopharm Co., Ltd. (688136)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Kexing Biopharm Co., Ltd., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Kexing Biopharm Co., Ltd. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH